<DOC>
	<DOC>NCT02248168</DOC>
	<brief_summary>The objectives of this study are to investigate issues or questions about MIRAPEX Tablets as shown below through the Post Marketing Surveillance (PMS) study upon approval. - Unexpected adverse events (especially, serious adverse events (SAEs)) - To find out the status of incidence of adverse events under actual practice - Factors on the safety profile - Factors on the efficacy profile</brief_summary>
	<brief_title>Post Marketing Surveillance And Special Surveillance for MirapexÂ® Tablet in Patients With Idiopathic Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Among the patients with idiopathic Parkinson's disease, from those receiving MIRAPEX Tablets first after a contract of the study to the requested number of cases will be consecutively enrolled without skipping Following patients are contraindicated. 1. Patients who are hypersensitive to MIRAPEX or its ingredients 2. Refer to the insert paper for other contraindication. Following patients should be carefully administered. 1. Patient with renal impairment 2. Refer to the insert paper for other precaution.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>